Jafron Biomedical Co., Ltd. services

Twenty-five national medical guidelines or consensus of critical illness, liver disease, etc., recommend Jafron hemoadsorption therapy. And the therapy was also included in 11 national health care guidelines and recommendations for the treatment of Covid-19, including China, Morocco, the UK, Russia, Thailand, Iran, the Philippines, Columbia, Italy, India, Vietnam. With products, technologies and therapies available in 8,000 hospitals across more than 80 countries, the annual clinical application of Jafron reached 5 million cases.

We are a team of more than 2800 employees and about 100 clinical medical experts as senior advisors and special advisors engaged in clinical trials and teaching courses.

Jafron owned International Quality Certification such as CE, ISO, EN ISO13485, and China GMP National Certification. It possesses 56,000 square meters of production factories, including an international standard ISO-7 clean workshop, an ISO-5 clean operation room, and an automated production line of hemoperfusion cartridges.

Jafron has solid research and development capabilities, with seven R&D centers and cooperative research institutions in Europe and China. It has collaborated with more than 80 international hospitals in clinical research and established several scientific research platforms such as the Guangdong Blood Purification Engineering Technology Research and Development Center, the Doctoral Research Workstation, the Postdoctoral Research Workstation, and the Academician Workstation. Meanwhile, Jafron has established a "Multi-Organ Support Therapy (MOST) Global Advisory Board," with six world-leading experts in the field of Blood purification and other 30 overseas experts.

The company owns products with ten series of more than 100 specifications, including Disposable Hemoperfusion Cartridge, Disposable Plasma Bilirubin Perfusion Adsorption Column, DNA Immunoadsorption Column, Hemoperfusion Machine and Blood Purification Machine, etc. Jafron provides new adsorption therapy, including "Combined Artificial Kidney," and "Double Plasma Molecular Adsorption System (DPMAS)," etc.